Vitamin D Deficiency, Supplementation, and Risk of Mortality and Chronic Disease: Evidence from Matched Cohorts in Israel and the US

Ariel Israel[1,2]*, Abraham Weizman[3], Sarah Israel[4],

Shai Ashkenazi[5,6], Eytan Ruppin[7], Eli Magen[8], Eugene Merzon[1,5], Shlomo Vinker[1]

Affiliations:

[1] Leumit Research Institute, Leumit Health Services; Tel-Aviv, Israel

[2] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Tel-Aviv, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

[4] Department of Clinical Microbiology and Infectious Diseases and Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem Israel

[5] Adelson School of Medicine, Ariel University; Ariel, Israel.

[6] Schneider Children's Medical Center, Petah-Tikva, Israel

[7] Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[8] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev; Beer Sheva, Israel

Corresponding author: Ariel Israel, Leumit Research Institute, Sprinzak 23, Tel-

Aviv 6473817, Israel, Telephone: +972-3-6970483. Fax: +972-76-8889190

Email: aisrael@leumit.co.il

Abstract word count: 250

Word count: 4,115

Tables count: 2

Figures count: 5

Abstract

Vitamin D deficiency is common worldwide and has been linked to excess morbidity and mortality, yet its causal role remains debated. We analyzed electronic health-record data from two large healthcare networks: Leumit Health Services (LHS) in Israel and the US-based TriNetX Research Network.

We examined more than 1.67 million serum 25-hydroxyvitamin D [25(OH)D] measurements from over 468,500 adults in LHS (2009-2020). In longitudinal matched-cohort analyses, we compared 13,352 severely deficient individuals (<10 ng/mL) to 12,352 with sufficient levels (>30 ng/mL) in LHS and validated findings in 223,000 matched pairs in TriNetX.

Severe deficiency was associated with increased risks of all-cause mortality, diabetes, diabetic retinopathy, myocardial infarction, cerebrovascular accident, dementia, dialysis, and foot/toe amputation, while skin malignancy showed an inverse association consistent with lower UV exposure.

To test modifiability, we fitted time-dependent Cox models in LHS incorporating monthly pharmacy-dispensed vitamin D supplementation. Supplementation was independently associated with dose-dependent risk reductions for mortality and most complications, but did not affect skin-malignancy risk, indicating supplementation effect is unlikely to be confounded by sun-exposure or other health-behavior factors.

These findings suggest severe vitamin D deficiency is a modifiable, clinically important risk factor, providing a strong rationale for evaluating targeted supplementation strategies in deficient populations.

Introduction

Vitamin D deficiency is widespread worldwide, particularly in populations with limited sun exposure or darker skin pigmentation[1–3]. While its role in bone health is well established, increasing evidence has linked low serum 25-hydroxyvitamin D [25(OH)D] levels to increased mortality[4] and a wide range of chronic conditions, including diabetes[5,6], cardiovascular disease[7], retinopathy, chronic kidney disease, foot ulcers, and neurodegenerative disorders[8–12]. However, despite extensive observational research, the causality of these associations remains disputed. One major challenge is disentangling whether low vitamin D levels are a contributing factor to poor health, or merely a biomarker of existing disease or adverse health behaviors.

Israel, like many countries, has experienced persistently high rates of diabetes-related complications, including lower extremity amputations, which is particularly elevated compared to other OECD nations[13,14]. At the same time, vitamin D deficiency is common in several demographic subgroups, particularly among individuals with limited sun exposure due to lifestyle, occupational, or cultural practices. Yet, large-scale population-level studies explicitly quantifying the long-term health risks of severe vitamin D deficiency in well-matched cohorts, and investigating whether such risks are modifiable, are scarce.

In this study, we leveraged the electronic health records (EHRs) of two large, demographically distinct populations—Leumit Health Services (LHS) in Israel and the US-based TriNetX Research Network—to assess the long-term clinical impact of severe vitamin D deficiency (<10 ng/mL) versus sufficiency (>30 ng/mL). Using tightly matched cohorts, we examined risks of mortality, diabetes, microvascular and macrovascular complications, and dementia, replicated findings across both healthcare systems for robustness, and evaluated

whether pharmacy-documented vitamin D supplementation conferred additional, dose-dependent risk reduction after adjusting for baseline 25(OH)D levels.

Our study is based on four sequential analyses (Figure 1):

80 **Analysis A:** We first explored the distribution of 25(OH)D in the LHS population using >1.67 million measurements from >470,000 individuals, modeling seasonal variation and the effect of vitamin D products on serum levels.

Analysis B: We evaluated the impact of severe vitamin D deficiency by following a matched LHS cohort of 12,352 severely deficient versus sufficient individuals, matched on age, sex, BMI, 85 smoking status, blood pressure, socioeconomic status, and geodemographic classification, using longitudinal time-to-event models to assess mortality and vitamin D-deficiency complications.

Analysis C: We validated these associations in the US-based TriNetX network by conducting an analogous analysis in matched cohorts of 206,600 individuals with severe deficiency and 206,600 with sufficient levels for the same outcomes.

90 **Analysis D:** Finally, we assessed the potential of vitamin D supplementation to mitigate these risks in LHS by fitting time-dependent models incorporating pharmacy-dispensed vitamin D supplementation as a time-varying covariate together with baseline 25(OH)D levels.

Results

95 ### Analysis A: Exploration of vitamin D distribution and of the impact of vitamin D supplementation purchases on serum 25(OH)D levels in LHS

We began our analysis with an exploratory assessment of serum 25(OH)D test results collected between 2009 and 2020 from LHS members aged 18 years or older. Serum 25(OH)D

levels demonstrated pronounced seasonal variation, consistent with fluctuations in sun exposure throughout the year. To model this variation, we applied a sinusoidal regression incorporating first- and second-order sine and cosine terms to log-transformed 25(OH)D levels. The fitted model revealed a robust periodic signal (see Supplementary Table 1), with peak vitamin D levels observed in late summer and a nadir around mid-February (Figure 1A).

To normalize for seasonality, we derived a population-based normogram (Figure 1B) that maps measured vitamin D levels to their expected nadir equivalents. This calendar-adjustment procedure was applied to all serum measurements, enabling generation of a seasonally adjusted annual exposure metric for each measured vitamin D levels. We then computed the average of these calendar-adjusted levels per person to reflect long-term vitamin D status. The resulting distribution (Figure 1C) highlights a substantial prevalence of severe deficiency (<10 ng/mL) and a smaller subgroup with sufficient average levels (>30 ng/mL). Severe deficiency was substantially more common in females, a pattern that aligns with known differences in sun exposure behaviors among women in certain cultural and religious communities within the population.

Analysis B: LHS Matched cohort of 25(OH)D deficient (<10ng/mL) vs. sufficient individuals - baseline

To evaluate the clinical consequences of severe vitamin D deficiency, we constructed a matched cohort comparing individuals with severe deficiency to those with sufficiency (flowchart in Supplementary Figure 1). The index date was defined as the first recorded serum 25(OH)D measurement for each individual from 2009 onward. Using the previously fitted seasonal-correction model, we calculated a day-of-year–adjusted mean 25(OH)D level for each individual

based on the index measurement and classified participants into two exposure groups: severely deficient (<10 ng/mL) and sufficient (>30 ng/mL).

For each severely deficient individual, we selected a matched control using 1:1 exact matching on age category, sex, smoking status, body-mass-index (BMI) category, hypertension status, socioeconomic status (SES), and geodemographic classification (general population, Arab, or Ultra-Orthodox) at the index date; among eligible controls, the individual with the closest BMI was selected.

Table 1 presents the baseline characteristics of the matched cohort, comprising 13,352 individuals with severe vitamin D deficiency (mean 25(OH)D < 10 ng/mL) and 12,352 matched controls with sufficient levels (> 30 ng/mL at baseline).

As expected from the matching design, the two groups were well balanced across all matching variables, with negligible standardized mean differences (SMD < 0.01 for age, BMI, weight and blood pressure measures). The matched groups (mean age 54.4 years; 67% female) showed no meaningful differences in the matched variables. Overall, the baseline risk factors in the two groups at the time of serum 25(OH)D testing were highly similar, supporting comparability between groups and strengthening the validity of the subsequent risk-association analyses.

We examined baseline clinical associations with severe vitamin D deficiency in the LHS matched cohort (Figure 3A). Despite rigorous matching on demographic and metabolic factors, individuals with severe deficiency showed markedly higher baseline prevalence of chronic conditions. Elevated odds were observed for diabetes-related and cardiovascular outcomes, including foot/toe amputation (OR 4.01, 95% CI [2.04 to 8.62], $p<10^{-5}$), diabetes mellitus (OR 1.23, 95% CI [1.15 to 1.31], $p<10^{-9}$), diabetic retinopathy (OR 1.69, 95% CI [1.45 to 1.99], $p<10^{-10}$), dementia (OR 1.89, 95% CI [1.53 to 2.33], $p<10^{-9}$), cerebrovascular accident (CVA) (OR

1.79, 95% CI [1.50 to 2.14], p<10^{-8}), and myocardial infarction (OR 1.40, 95% CI [1.25 to 1.57], p<10^{-8}). In contrast, the odds of skin malignancy were markedly reduced (OR 0.44, 95% CI [0.31 to 0.61], p<10^{-6}), suggesting lower cumulative skin ultraviolet (UV) exposure in the group with low 25(OH)D serum levels.

Analysis C: US TriNetX matched cohort of 25(OH)D deficient (<10ng/mL) vs. sufficient individuals - baseline

To validate these findings, we performed a similar analysis in an independent population using TriNetX, a global federated health research network that aggregates electronic health records from more than 70 healthcare organizations covering over 120 million patients. Eligible members of the US network, with a documented serum 25(OH)D measurement obtained within one year of a recorded BMI value. Individuals with severe deficiency (<10 ng/mL) were compared with those having sufficient levels (>30 ng/mL) using propensity-score matching on age, sex, smoking status, Black or African-American ethnicity, essential hypertension, diabetes mellitus diagnosis, BMI, blood-pressure categories, and hemoglobin A1c categories. Table 2 presents the clinical characteristics of the cohort at baseline, showing well balanced groups and near-identical distributions of age (mean ~ 54 years), sex (≈ 65 % female), cardiometabolic risk factors, and laboratory measures.

Baseline clinical associations in TriNetX (Figure 3B) were directionally consistent with those in the LHS cohort, though somewhat attenuated, likely because cohort classification in LHS used season-adjusted 25(OH)D levels, whereas TriNetX relied on unadjusted measurements and forced matching for diabetes-related laboratory variables, which may have partially diluted some of the associations.

Nevertheless, the TriNetX cohort showed the same pattern of higher odds of chronic conditions at baseline. Notably, the deficient group had significantly higher rates of diabetes-related and cardiovascular complications, including foot/toe amputation (OR 1.81, 95 % CI [1.60–2.04], p = 6.2×10^{-21}), diabetic retinopathy (OR 1.36 [1.30–1.41], p < 10^{-3}), dementia (OR 1.28 [1.21–1.35], p < $10^{-1\square}$), CVA (OR 1.41 [1.37–1.46], p < 10^{-12}), myocardial infarction (OR 1.45 [1.40–1.50], p < $10^{-1\square\square}$), and hemodialysis (OR 1.65 [1.56–1.74], p < $10^{\square\square\square}$). In contrast, the odds of skin malignancy were significantly lower in the vitamin D-deficient group (OR 0.72, 95 % CI [0.69–0.76], p = $6.7 \times 10^{\square\square\square}$), again suggesting lower cumulative ultraviolet skin exposure among individuals with low 25(OH)D levels.

The consistency of these baseline differences across two large and demographically distinct cohorts reinforces the association between severe vitamin D deficiency and a broad profile of chronic disease burden not attributable to age, sex, BMI, smoking status, blood pressure, ethnicity, or other matched covariates.

Longitudinal impact of 25(OH)D deficiency in the LHS and TriNetX cohorts

To evaluate the longitudinal impact of vitamin D deficiency, we conducted survival analyses excluding individuals who had the outcome of interest at baseline or who developed it within six months of the baseline measurement. Both cohorts were then followed longitudinally for up to 10 years from the index date, applying a six-month safety lag. In LHS, we used Cox proportional-hazards models to estimate adjusted hazard ratios (aHR) in the matched cohort with adjustment for the following covariates: age (continuous), sex, socioeconomic status (fine categories), baseline diabetes (defined by ICD-9 diagnosis or HbA1c >6.5), smoking status (never, past, current, or missing), BMI (fine categories plus an offset from the category lower boundary), kidney function (GFR categories), and albuminuria (urinary albumin/creatinine

190   categories). Figure 4 (left panel) displays the Kaplan–Meier survival curves together with the

aHRs, 95% confidence intervals, and p-values for LHS.

We performed analogous analyses in TriNetX, using Cox proportional-hazards models to

estimate hazard ratios (HRs) for the same outcomes (Figure 4, right panel).

This analysis revealed a consistently higher cumulative incidence of mortality and major

195   outcomes during follow-up among individuals with severe vitamin D deficiency in both cohorts.

LHS cohort:

- All-cause mortality: cumulative 8-year incidence ≈ 14 % in the deficient group vs ≈ 8 % in controls; aHR = 2.57 (95 % CI [2.38–2.79], p < $10^{³□□}$)

- Foot/Toe amputation: aHR = 3.59 ([2.15–5.98], p < $10^{¹□}$)

200   - Myocardial infarction: aHR = 1.26 ([1.10–1.46], p = 0.0009)

- Cerebrovascular accident: aHR = 1.54 ([1.32–1.78], p < $10^{□□}$)

- Dementia: aHR = 1.35 ([1.20–1.52], p = 0.02)

- Diabetic retinopathy: aHR = 1.73 ([1.42–2.10], p < $10^{□□}$)

- Dialysis: aHR = 1.84 ([1.13–2.99], p = 0.0005)

205   - Skin malignancy: consistently lower in the deficient group (aHR = 0.57 [0.47–0.70], p < $10^{□¹³}$)

TriNetX cohort:

- All-cause mortality: HR = 1.59 (95 % CI [1.55–1.63], p < $10^{³□□}$)

- Foot/toe amputation: HR = 1.54 ([1.38–1.72], p < $10^{□¹³}$)

210   - Myocardial infarction: HR = 1.37 ([1.33–1.42], p < $10^{□□¹}$)

- Cerebrovascular accident: HR = 1.36 ([1.31–1.40], p < $10^{□□□}$)

- Dementia: HR = 1.14 ([1.08–1.19], p < $10^{□□}$)

- Diabetic retinopathy: HR = 1.34 ([1.27–1.42], $p < 10^{-2\square}$)

- Hemodialysis: HR = 2.07 ([1.96–2.19], $p < 10^{-1\square^1}$)

- Skin malignancy: significantly lower in the deficient group, HR = 0.66 ([0.63–0.69], $p < 10^{\square\square\square}$)

In both cohorts, the divergence in risk between the deficient and sufficient groups increased over time, even after excluding events that occurred prior to the index date or during the initial six-month lag period. These associations remained materially unchanged when applying a 12-month lag period to further minimize reverse causation (Supplementary Figure 2).

The replication of these trends in matched cohorts across two large, geographically and structurally distinct healthcare systems reinforces the robustness and generalizability of the observed associations. The consistency in magnitude, direction, and timing of risk divergence across datasets supports a potential contributory role of severe vitamin D deficiency in chronic disease progression and mortality.

Modeling vitamin D supplementation impact on 25(OH)D levels

To evaluate whether vitamin D represents a modifiable risk factor, we investigated the effect of supplementation on 25(OH)D levels and downstream clinical outcomes. We began by decomposing the variation in serum 25(OH)D levels into two components: one attributable to largely non-modifiable demographic and structural factors—such as BMI, sex, ethnicity, and socioeconomic status—and another potentially modifiable through supplementation. Using a multivariable linear regression model, we predicted log-transformed 25(OH)D levels based on sex, ethnic group, socioeconomic status, BMI category, age, and seasonal harmonics. This model

235 explained 25.4% of the variance in 25(OH)D levels ($R^2 = 0.254$) in the population (Supplementary Table 2).

To isolate the contribution of vitamin D supplementation, we quantified the total intake in international units (IU) from all vitamin D products purchased through LHS pharmacies during each of the 4 months preceding a 25(OH)D test, as well as over quarterly and yearly periods. We

240 then modeled the difference between the observed serum 25(OH)D levels and those predicted based on demographic characteristics and BMI, regressing this residual on estimated supplementation amounts, aggregated into predefined time-period bins. Supplement use in the months prior to testing had the strongest effect, with diminishing impact for more distant time windows (Supplementary Table 3). Together, supplementation variables explained an additional

245 9.% of the variance in 25(OH)D levels not captured by baseline characteristics, demonstrating a quantifiable effect of supplement use on serum 25(OH)D levels.

Analysis D: Assessing the independent effect of vitamin D supplementation

To assess how vitamin D supplementation influences clinical outcomes, we followed 260,562 Leumit Health Services (LHS) members aged ≥30 years with at least one serum

250 25(OH)D measurement, representing 84.4% of members in this age range. We excluded individuals for whom no serum 25(OH)D test could be found while not under supplementation (>2 ng/mL predicted contribution), yielding 247,848 participants with baseline 25(OH)D levels available for analysis. For this cohort, we computed two variables:

- **Calendar-adjusted baseline serum 25(OH)D concentration**, categorized as <5, 5–10, 10–

255 15, 15–20, and >20 ng/mL (reference group); and

- **Vitamin D supplementation**, modeled as a time-dependent covariate reflecting the predicted monthly increase in serum 25(OH)D based on pharmacy purchase data, categorized as <0.2 ng/mL (reference), 0.2–5 ng/mL, 5–10 ng/mL, and >10 ng/mL serum-equivalent.

We fitted joint multivariable Cox proportional-hazards models including both baseline 25(OH)D categories and vitamin D supplementation as a time-dependent covariate to estimate associations with all-cause mortality and major clinical outcomes. Models were adjusted for age, sex, smoking status, socioeconomic status, BMI (fine categories plus offset), blood pressure, estimated GFR, albuminuria category, baseline diabetes, and hypertension. Results are shown in Figure 5.

For mortality (Figure 5A), baseline vitamin D deficiency was associated with a graded, dose-dependent increase in risk: HR = 1.50 [1.41–1.58] for <5 ng/mL; HR = 1.32 [1.28–1.37] for 5–10 ng/mL; HR = 1.15 [1.11–1.19] for 10–15 ng/mL; and HR = 1.06 [1.03–1.10] for 15–20 ng/mL (reference > 20 ng/mL; all p < 0.001). Vitamin D supplementation was independently protective in a dose-dependent fashion: HR = 0.69 [0.65–0.73] for > 10 ng/mL serum-equivalent; HR = 0.76 [0.73–0.80] for 5–10 ng/mL; and HR = 0.80 [0.78–0.82] for 0.2–5 ng/mL (all p < 10^{-32}).

For diabetes mellitus (Figure 5B), lower baseline vitamin D was strongly associated with higher risk: HR = 1.51 [1.41–1.62] for < 5 ng/mL; HR = 1.32 [1.26–1.38] for 5–10 ng/mL; HR = 1.20 [1.16–1.25] for 10–15 ng/mL; and HR = 1.11 [1.07–1.16] for 15–20 ng/mL (all p < $10^{\square\square}$). Supplementation was again protective: HR = 0.86 [0.84–0.89] for 0.2–5 ng/mL; HR = 0.86 [0.81–0.92] for 5–10 ng/mL; and HR = 0.80 [0.73–0.88] for > 10 ng/mL (all p < 0.001).

For diabetic retinopathy (Figure 5C), baseline deficiency was associated with increased risk (HR = 1.90 [1.63–2.20] for < 5 ng/mL; HR = 1.54 [1.39–1.71] for 5–10 ng/mL; HR = 1.30 [1.18–1.44] for 10–15 ng/mL; all p < $10^{\square\square}$), while supplementation was protective (HR = 0.79 [0.73–0.85] for 0.2–5 ng/mL; p < $10^{\square 1 \square}$).

For myocardial infarction (Figure 5D), low baseline vitamin D was linked to higher risk (HR = 1.42 [1.25–1.61] for < 5 ng/mL; HR = 1.33 [1.23–1.42] for 5–10 ng/mL; HR = 1.27 [1.19–1.35] for 10–15 ng/mL; HR = 1.18 [1.11–1.25] for 15–20 ng/mL; all p < 10$^{\square\square}$), and supplementation again showed significant protection (HR = 0.81 [0.77–0.86]; p < 10$^{\square 1\square}$).

For foot/toe amputation (Figure 5E), a strong baseline dose-response was evident, with HR = 2.19 [1.56–3.08] for < 5 ng/mL; HR = 1.69 [1.34–2.14] for 5–10 ng/mL; HR = 1.38 [1.11–1.72] for 10–15 ng/mL. No significant protective effect of supplementation was detected, likely due to the limited number of amputation events under supplementation.

For skin malignancy (Figure 5F), baseline vitamin D levels showed an inverse association, consistent with lower UV exposure in vitamin D–deficient individuals, whereas supplementation showed no significant effect (HRs near 1.0), serving as a negative-control outcome.

These findings demonstrate that lower baseline vitamin D levels confer increased risks for multiple outcomes, while supplementation—modeled independently of baseline status—was associated with dose-dependent risk reductions for most endpoints, supporting the modifiability of these risks through improved vitamin D status.

These findings indicate that vitamin D supplementation is independently and strongly associated with reduced risk of multiple adverse outcomes, even after adjusting for baseline vitamin D levels and demographic confounders. The consistent, monotonic pattern in cardiovascular, metabolic, and mortality endpoints strongly supports a modifiable, causal role for vitamin D status in chronic disease prevention.

Risk Reduction and Number Needed to Treat

To evaluate the clinical utility of vitamin D supplementation, we estimated the 10-year number needed to treat (NNT) to prevent one all-cause mortality event, stratified by age group ($\geq$30, $\geq$50, and $\geq$70 years), baseline serum 25(OH)D category, and the predicted supplementation-related increase in serum levels (Figure 6). Because mortality represents the only outcome not subject to potential competing-risk bias, NNT estimation was restricted to all-cause mortality.

Protective effects were evident at all ages and for all baseline vitamin D categories below 20 ng/mL, with NNTs declining sharply with advancing age. Among participants with baseline 25(OH)D < 5 ng/mL, NNTs at age 30 ranged from 142–159 depending on supplementation dose, but improved markedly to 33.5–36.2 at age 50 and as low as 9.7–10.5 at age 70. For those starting at 5–10 ng/mL, NNTs similarly decreased from 191–248 at age 30 to 54.0–71.6 at age 50 and 12.9–15.6 at age 70. At baseline levels of 10–15 ng/mL, NNTs dropped from 229–391 at age 30 to 77.2–126 at age 50 and 15.7–22.9 at age 70. Even among individuals with baseline 15–20 ng/mL, NNTs remained clinically meaningful in older adults, declining from 300–492 at age 30 to 100–163 at age 50 and 18.3–27.7 at age 70.

This pronounced age-gradient reflects the rising absolute mortality risk in older adults and highlights the particularly strong preventive potential of vitamin D supplementation in individuals with severe or moderate deficiency, especially at age 70 years and above. Collectively, these results show that vitamin D supplementation could yield substantial clinical benefit, especially for those with baseline 25(OH)D < 10 ng/mL, by preventing mortality events at relatively low NNTs in older populations.

Discussion

In this dual-cohort large-scale observational study leveraging real-world data from over 120 million patients in two countries, we demonstrate that long-term 25(OH)D deficiency is strongly associated with elevated risks of mortality, metabolic disease, cardiovascular events, and microvascular complications. Importantly, our analyses suggest that vitamin D supplementation, modeled through pharmacy records and validated serum responses, is associated with significant reductions in risk across a wide range of clinical outcomes. The protective associations were consistent, dose-dependent, and remained significant even after controlling for confounding demographic, behavioral, and socioeconomic factors.

The LHS matched cohort design allowed for tight baseline matching of demographic and clinical risk factors, including BMI, blood pressure, diabetes, smoking status, and kidney disease. Findings were replicated in an independent, US-based federated health network (TriNetX), enhancing external validity. A major strength of this study is the integration of detailed laboratory, demographic, and pharmacy data from a national health organization, enabling precise classification of baseline vitamin D status and estimation of serum responses to supplementation. We leveraged these data to construct a time-dependent covariate for vitamin D supplementation, derived from pharmacy-dispensed records and calibrated to predict serum 25(OH)D changes over time. This approach distinguished the modifiable effect of supplementation from the confounding influence of demographic, socioeconomic, and obesity-related determinants of vitamin D deficiency.

The supplementation covariate was based on the residual variation in 25(OH)D unexplained by demographic and clinical predictors (age, sex, BMI, ethnicity, socioeconomic status, and season).

345   As a result, subgroup differences in these baseline determinants were inherently accounted for, while the same variables were also included as covariates in the multivariable Cox models. This design minimizes bias from population heterogeneity and provides a robust framework for assessing the independent, time-updated effect of vitamin D supplementation on outcomes.

Our findings revealed strikingly low numbers needed to treat (NNTs) for all-cause mortality,
350   especially among adults ≥70 years with severe vitamin D deficiency, where NNTs approached 10—comparable to or better than many established preventive therapies such as statins or antihypertensives in moderate-risk populations. Even moderate supplementation (predicted serum increase of 10–20 ng/mL) in this group yielded substantial absolute benefit. Importantly, benefit extended beyond the severely deficient: individuals with baseline 25(OH)D of 15–20 ng/mL also
355   showed meaningful reductions in mortality risk, with NNTs of roughly 18–28 depending on supplementation level. These results highlight vitamin D supplementation as a scalable, low-cost intervention with significant public-health potential when targeted to individuals with suboptimal baseline levels.

Previous randomized controlled trials (RCTs) of vitamin D supplementation have yielded
360   inconsistent results for chronic disease and mortality outcomes[18–21]. Several factors likely explain this discrepancy. Most RCTs enrolled participants regardless of baseline vitamin D status, resulting in limited power to detect benefits confined to the severely deficient subgroups, where our strongest associations were observed, particularly among older adults. In addition, background supplement use in placebo groups and incomplete adherence diluted between-group
365   differences in achieved 25(OH)D levels, leading to underestimation of true effects. Moreover, many trials used fixed low doses, without achieving the serum repletion levels associated with reduced mortality and morbidity in our real-world data. These limitations help reconcile the

apparent divergence between large pragmatic RCTs and the consistent, dose-dependent associations observed in our cohorts.

370   The biological mechanisms underlying these protective effects remain to be fully elucidated. One plausible pathway involves modulation of the human microbiome—either through direct immune effects or by altering microbial or protozoal species that drive chronic inflammation, insulin resistance, or tissue injury[22–27]. Supporting this hypothesis is the breadth of conditions impacted—including diabetes, cardiovascular disease, and all-cause mortality—which may share
375   common microbial or immune-mediated origins. A particularly notable observation was the significant reduction in foot and toe amputations among supplemented individuals. Given that such amputations are frequently precipitated by persistent infection, this finding further supports a microbiologically mediated mechanism[28]. The historically high rate of amputations observed in our country has remained inadequately explained; our findings suggest that severe vitamin D
380   deficiency, which is disproportionately prevalent in certain population subgroups, may contribute to this excess risk.

This study has limitations. As an observational analysis, residual confounding cannot be entirely excluded despite extensive matching, adjustment, and validation across two independent cohorts. Vitamin D supplementation may also co-occur with other unmeasured health-promoting
385   behaviors. In addition, our exposure definition relied on pharmacy-dispensed purchases within LHS–affiliated pharmacies and may not fully capture over-the-counter acquisitions through untracked channels. Nevertheless, the strength, consistency, and dose-dependent pattern of associations across cohorts support a genuine underlying relationship. Although standard Cox models treat death as a censoring event, mortality, being itself elevated among deficient
390   individuals, functions as a competing outcome. Because this would attenuate rather than inflate

risk estimates, a competing-risk framework would likely reinforce rather than weaken the observed associations.

In conclusion, our findings suggest that vitamin D deficiency is a prevalent and potentially modifiable contributor to morbidity and mortality. Vitamin D supplementation
395 represents a low-cost, low-risk intervention with broad preventive potential. Public health initiatives to improve detection and treatment of deficiency—particularly among high-risk groups with limited sun exposure, darker skin pigmentation, dietary insufficiency, or structural barriers to care—warrant prioritization. In the United States, Black/African-American populations experience disproportionately higher rates of vitamin D deficiency as well as elevated burdens of
400 diabetes and premature mortality. Our analyses suggest that vitamin D deficiency could partly contribute to these disparities. Interventional studies targeting severely deficient individuals, including under-served minority populations would help quantify the potential benefit and inform public-health policy and clinical practice.

Methods

Overview

We conducted a retrospective observational study across two healthcare systems (Israel: Leumit Health Services, LHS; United States: TriNetX). Analyses were prespecified and categorized as cross-sectional (baseline prevalence) or longitudinal (time-to-event). Figure 1 summarizes analytic populations, eligibility, exposure definitions, matching/PSM, and lags.

Participants

- Analysis A (LHS): adults ≥18 years with ≥1 serum 25(OH)D test in 2009–2020 (index date = first qualifying test).

- Analyses B–D (LHS): adults ≥30 years (index = first qualifying test); a 6-month lag excluded events within the first year after index. Sensitivity analyses were also repeated with a 12-month lag, yielding similar results (Supplementary Figure 2).

- Analysis C (TriNetX): adults ≥18 years, with harmonized outcome definitions; propensity score matching (PSM) applied as below.

Full inclusion/exclusion criteria are detailed in Figure 1.

Variables

Covariates (LHS): Cox models were fitted after adjustment for age, sex, smoking status, socioeconomic status, BMI (fine categories + offset), eGFR category, albuminuria category, baseline diabetes (ICD-9 or HbA1c ≥6.5); a 6-month lag excluded early events.

Covariates (TriNetX): we used propensity score matching (PSM) using age, sex, ethnicity, race, diabetes diagnosis, BMI, eGFR, and hemoglobin A1c categories); a 6 months lag excluded early events.

- **Outcomes:** all-cause mortality and clinical outcomes (MI, heart failure, dialysis, diabetic retinopathy, foot/toe amputation, dementia, skin malignancy), as defined in Supplementary Table 4.

Data Sources/Measurement

We used de-identified electronic health records (EHRs) from two distinct cohorts Leumit Health Services (LHS), a nationwide Israeli health maintenance organization and the TriNetX US Collaborative Network, which aggregates de-identified EHRs from over 70 health care organizations (HCOs). LHS and TriNetX EHR sources included demographics, diagnoses (ICD-9/ICD-10 as applicable), labs, and pharmacy dispensing. 25(OH)D serum levels were reported in ng/mL units (1 ng/mL = 2.5 nmol/L), and calendar-adjusted for seasonality (see Seasonal normalization). Medical conditions were defined based on diagnosis codes and lab thresholds. An exploratory analysis (Analysis B) was performed using a curated list of ~200 common conditions developed at the Leumit Research Institute, and used for further validation. The TriNetX platform enables prospective-style retrospective analyses using standardized temporal alignment.

Bias and sensitivity analyses

We mitigated confounding by (i) exact matching (LHS Analysis B) and covariate adjusted regressions, (ii) PSM with balance diagnostics (TriNetX Analysis C), and (iii) multivariable adjustment with time-dependent supplementation (LHS Analysis D). To reduce reverse causation, we excluded prevalent events and applied a 6-month lag in all longitudinal analyses (B–D).

Seasonal Normalization of Serum 25(OH)D levels

25(OH)D levels display marked seasonal variation. To standardize values across measurement dates, we fitted a sinusoidal regression model using log-transformed 25(OH)D values with first- and second-order sine and cosine terms to model annual periodicity:

$$\log(\text{VitaminD}) \sim \beta_0 + \beta_1 \sin t + \beta_2 \cos t + \beta_3 \sin 2t + \beta_4 \cos 2t$$

where t denotes the day of the year in radians. Adjusted values were computed by estimating serum levels at the population trough (February 14), using the fitted model to remove seasonal effects.

Data Extraction and Preprocessing

Structured EHR data from LHS were queried using T-SQL. Python 3.11 and the Pandas library were used for data preprocessing. Each patient record was anonymized using an internal study ID. Baseline covariates, including sex, age, BMI category, socioeconomic status, ethnicity, and smoking status, were extracted as of the index date.

Matched Cohort Construction (LHS)

To evaluate the long-term impact of severe deficiency, we constructed a 1:1 matched cohort of a group of deficient individuals with calendar-adjusted vitamin D levels <10 ng/mL and those with >30 ng/mL. Matching was exact on age category, sex, smoking status, BMI and blood pressure category, ethnic sector (general, Arab, ultra-Orthodox), socioeconomic status, and year of LHS enrollment, ensuring balance in major demographic and metabolic risk factors. Baseline tables

and models report groups by vitamin D status categories; the sufficiency group (>30 ng/mL)
serves as the reference category.

Outcome Discovery in LHS

470   Approximately 200 common medical conditions, defined using validated ICD-9 code groups
curated by Leumit Research Institute, were screened in the matched cohort. Cox proportional
hazards models were used to compare cumulative incidence between groups, adjusting for
covariates. False discovery rate (FDR) control was applied to identify conditions with significant
differences.

TriNetX Validation Cohort

475   For external validation, we compared TriNetX patients with 25(OH)D <10 ng/mL to those with
>30 ng/mL. Propensity score matching was performed on age, sex, African American ethnicity,
BMI category, obesity diagnosis, and smoking status. Post-matching balance was assessed using
standardized mean differences. Conditions identified as FDR-significant in LHS were validated
using harmonized definitions in TriNetX with a 6-month lag to exclude early events.

480   ### Vitamin D supplementation estimation

All vitamin D–containing product purchases were extracted from Leumit Health Services (LHS)
pharmacy records. Each product in the catalog was assigned a total vitamin D content (expressed
in kilo–international units, kIU) based on its labeled concentration and the number of dosage
units per package.

485   To quantify the contribution of supplementation to serum 25-hydroxyvitamin D [25(OH)D] levels, we implemented a two-stage regression framework:

1. **Baseline Model**: A multivariable linear regression was used to predict log-transformed serum 25(OH)D levels based on demographic and structural variables, including age, sex, BMI category, ethnicity, socioeconomic status, and seasonal harmonics (sine and cosine terms for date). This model explained 25.4% of the variance in serum 25(OH)D levels.

2. **Supplementation Model**: The residuals from the baseline model were regressed on lagged vitamin D supplement purchases. Total purchased vitamin D (in kIU) was aggregated across time bins—1 month, 3 months (quarter), and 12 months (year) preceding the test date. Each time bin was assigned an empirically estimated coefficient reflecting its weighted contribution to the serum level at the target date.

Validation of Supplementation Model and Avoidance of Reverse Causation

Although clinical factors such, as impaired renal function, may influence vitamin D metabolism, no clinical or demographic variables were included in the supplementation model to avoid potential reverse causation. The baseline model, which predicted log-transformed serum 25(OH)D levels using demographic and temporal variables, explained 25.4% of the total variance. The second-stage model, which incorporated only weighted vitamin D supplementation exposures based on pharmacy purchase data, explained an additional 9.0% of the residual variance. Together, the two-stage model accounted for ~35.4% of the variance in serum 25(OH)D, providing strong internal validation and confirming the measurable, dose-dependent impact of documented supplementation.

Classification of Vitamin D Status

Baseline vitamin D status was defined based on each individual's first calendar-adjusted serum 25(OH)D measurement, grouped into the following categories: 0–5 ng/mL, 5–10 ng/mL, 10–15 ng/mL, 15–20 ng/mL, and >20 ng/mL (reference category). For each individual and each calendar month from the index date to censoring, we estimated the serum contribution of vitamin D supplementation, expressed in ng/mL equivalents. These values were grouped into supplementation exposure categories: 0–0.2 ng/mL (reference), 0.2–5 ng/mL, 5–10 ng/mL, and >10 ng/mL. This time-varying covariate was incorporated into Cox proportional hazards models to evaluate the independent effects of supplementation.

Survival Analysis Using Time-Dependent Supplementation

We used time-dependent Cox proportional hazards models to evaluate supplementation effects on mortality and clinical outcomes. Person-time was split into monthly intervals per patient, updating the supplementation covariate from pharmacy dispensing. Models jointly included baseline 25(OH)D categories (calendar-adjusted; reference 20–30 ng/mL) and vitamin D supplementation categories (time-dependent; reference <0.2), and were adjusted for age, sex, smoking status, socioeconomic status, BMI (fine categories plus offset), GFR category, albuminuria category, and baseline diabetes. A 6-month lag was applied, excluding events occurring within the first year after the index date.

Absolute Risk Reduction and Number Needed to Treat (NNT)

ARR and NNT were calculated at 10 years:

1. **Stratification**: Individuals were grouped by baseline vitamin D status.

2. **Time-Dependent Cox Model**: Fitted with time-updated supplementation bins.

3. **Reference Profile**: Defined using mean values from the <0.2 ng/mL supplementation group.

4. **Survival Estimation**: Baseline and supplemented survival probabilities were computed.

5. **ARR and NNT Calculation**:

   ○ ARR(t) = S1(t) - S0(t)

   ○ NNT(t) = 1 / |ARR(t)|

These were estimated per supplementation category and vitamin D stratum.

535 ### Statistical Analyses

Categorical variables were compared using Fisher's exact test. Continuous variables used two-sample t-tests. Logistic regression was used for odds ratios (ORs) with 95% confidence intervals (CIs). Longitudinal outcomes were analyzed with Cox proportional hazards models. Kaplan-Meier curves were used to visualize survival. Death and disenrollment were treated as censoring

540 events in all models. Given the strong association between deficiency and mortality itself, competing-risk modeling would likely yield even higher relative hazards for nonfatal outcomes.

All analyses were performed using R 4.4 and Python 3.11.

Generative AI statement

ChatGPT (version 4o, OpenAI) was used to assist with language refinement for improved clarity

545 and flow, and to provide support with coding tasks related to data analysis scripts. All content was reviewed and verified by the authors to ensure accuracy and integrity.

Ethics Statement

All analyses of Leumit Health Services (LHS) data were performed retrospectively on fully anonymized electronic health records under institutional review board approval (Leumit Health Services IRB approval no. LEU-0020-24), with a waiver of informed consent granted because the study posed minimal risk and used de-identified data.

Analyses using the US TriNetX Research Network were conducted on de-identified aggregate data provided under data-use agreements with participating healthcare organizations and were therefore not considered human-subjects research; these analyses were compliant with the US Health Insurance Portability and Accountability Act (HIPAA) and local institutional guidelines.

Acknowledgements

Funding

This study was funded internally by Leumit Health Services.

Conflict of Interest

The Authors have declared that there are no conflicts of interest in relation to the subject of this study.

References

565   1.   Hilger, J. *et al.* A systematic review of vitamin D status in populations worldwide. *British Journal of Nutrition* **111**, 23–45 (2014).

2.   Holick, M. F. Vitamin D Deficiency. *New England Journal of Medicine* **357**, 266–281 (2007).

3.   Cashman, K. D. *et al.* Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr* **103**,

570   1033–1044 (2016).

4.   Gotsman, I. *et al.* Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. *Eur J Heart Fail* **14**, 357–366 (2012).

5.   Scragg, R. *et al.* Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose

575   tolerance and diabetes mellitus. *Diabetes Res Clin Pract* **27**, 181–188 (1995).

6.   Pittas, A. G., Lau, J., Hu, F. B. & Dawson-Hughes, B. The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* **92**, 2017–2029 (2007).

7. Judd, S. E. & Tangpricha, V. Vitamin D deficiency and risk for cardiovascular disease. *Am J Med Sci* **338**, 40–4 (2009).

8. Usluogullari, C. A. *et al.* The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. *BMC Endocr Disord* **15**, 33 (2015).

9. Liu, L. C. Y. *et al.* Vitamin D status and outcomes in heart failure patients. *Eur J Heart Fail* **13**, 619–625 (2011).

10. Liu, L. *et al.* The role of vitamin D in diabetic foot ulcer; an umbrella review of meta-analyses. *Front Nutr* **11**, (2024).

11. Afzal, S., Bojesen, S. E. & Nordestgaard, B. G. Low 25-Hydroxyvitamin D and Risk of Type 2 Diabetes: A Prospective Cohort Study and Metaanalysis. *Clin Chem* **59**, 381–391 (2013).

12. Vasdeki, D. *et al.* Vitamin D Supplementation: Shedding Light on the Role of the Sunshine Vitamin in the Prevention and Management of Type 2 Diabetes and Its Complications. *Nutrients* **16**, 3651 (2024).

13. Diabetes-Related Lower Extremity Amputation Rates per 100,000 Population | Commonwealth Fund. https://www.commonwealthfund.org/international-health-policy-center/system-stats/diabetes-related-lower-extremity-amputation.

14. OECD Reviews of Health Care Quality. OECD Reviews of Health Care Quality: Israel, raising standards. *https://www.oecd.org/content/dam/oecd/en/publications/reports/2012/10/oecd-reviews-of-health-care-quality-israel-2012_g1g1fd99/9789264029941-en.pdf* (2012).

15. Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *The BMJ* **375**, e067873 (2021).

16.   Israel, A. *et al.* Type 2 Diabetes in Patients with G6PD Deficiency. *New England Journal of Medicine* **391**, 568–569 (2024).

17.   Palchuk, M. B. *et al.* A global federated real-world data and analytics platform for research. *JAMIA Open* **6**, (2023).

18.   Zittermann, A. *et al.* Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. *Eur Heart J* **38**, 2279–2286 (2017).

19.   Davidson, M. B., Duran, P., Lee, M. L. & Friedman, T. C. High-Dose Vitamin D Supplementation in People With Prediabetes and Hypovitaminosis D. *Diabetes Care* **36**, 260–266 (2013).

20.   Chen, L. *et al.* Vitamin D supplementation can improve the 28-day mortality rate in patients with sepsis-associated acute kidney injury. *Ren Fail* **46**, (2024).

21.   Zhang, Y. *et al.* Association between vitamin D supplementation and mortality: systematic review and meta-analysis. *BMJ* l4673 (2019) doi:10.1136/bmj.l4673.

22.   Rasheed, Z. *et al.* Toxoplasmosis in immunocompetent Saudi women: Correlation with vitamin D. *Women's Health* **17**, (2021).

23.   Schwalfenberg, G. K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. *Mol Nutr Food Res* **55**, 96–108 (2011).

24.   Merzon, E. *et al.* Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS Journal* **287**, 3693–3702 (2020).

25. Israel, A. *et al.* Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study. *Intern Emerg Med* **17**, 1053–1063 (2022).

26. Lagishetty, V., Liu, N. Q. & Hewison, M. Vitamin D metabolism and innate immunity. *Mol Cell Endocrinol* **347**, 97–105 (2011).

27. Singh, P., Rawat, A., Alwakeel, M., Sharif, E. & Al Khodor, S. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals. *Sci Rep* **10**, 21641 (2020).

28. Joshi, M. *et al.* Modulatory role of vitamins A, B3, C, D, and E on skin health, immunity, microbiome, and diseases. *Pharmacological Reports* **75**, 1096–1114 (2023).

Author contributions:

Conceptualization: AI, EMe, EMa

Methodology: AI, EMe

Investigation: AI, SI, EMe

Writing – original draft: AI

Writing – review & editing: AI, AW, SI, SA, SV, EMa, EMe

Materials & Correspondence: Correspondence and requests for materials should be addressed to AI

645 **Funding:** This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S.
650 Government.

Conflict of Interest Statement: The Authors declare that there are no conflicts of interest in relation to the subject of this study.

655 **Abbreviations**:

aOR: adjusted Odds Ratio

BMI: Body Mass Index

BP: Blood pressure

CNS: Central nervous system

660 EHR: Electronic health records

HR: Hazard Ratio

ICD-9: International Classification of Diseases, Ninth Revision

LHS: Leumit Health Services

OR: Odds Ratio

665 PO: Per os

PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

Table 1. Demographic and clinical characteristics of the LHS matched cohort at baseline (Analysis B)

		Deficiency 25(OH)D below 10ng/mL	Sufficiency 25(OH)D above 30ng/mL (reference)	P-value	Odds Ratio	SMD
N		12,352	12,352			
Age (years)		54.4 ± 14.8	54.5 ± 14.6	0.625		-0.006
Sex	Female	8,278 (67.0 %)	8,278 (67.0 %)	1.000	1.00 [0.95 to 1.05]	
	Male	4,074 (33.0 %)	4,074 (33.0 %)	1.000	1.00 [0.95 to 1.05]	
Weight (kg)		75.8 ± 16.8	75.7 ± 16.6	0.833		0.003
Height (cm)		165 ± 9	165 ± 10	0.001		-0.044
Body Mass Index (BMI) (kg/m^2)		28.0 ± 5.7	28.0 ± 5.7	0.508		0.009
	<18.5 Underweight	182 (1.68 %)	191 (1.80 %)	0.497	0.93 [0.75 to 1.15]	
	18.5-24.9 Normal	3,280 (30.22 %)	3,248 (30.64 %)	0.514	0.98 [0.92 to 1.04]	
	25-29.9 Overweight	3,866 (35.62 %)	3,734 (35.23 %)	0.549	1.02 [0.96 to 1.08]	
	>=30 Obese	3,524 (32.47 %)	3,427 (32.33 %)	0.827	1.01 [0.95 to 1.07]	
	~missing~	1,500 (12.14 %)	1,752 (14.18 %)			
Smoking status	Non-smoker	9,347 (79.22 %)	9,657 (79.84 %)	0.235	0.96 [0.90 to 1.03]	
	Past smoker	213 (1.81 %)	254 (2.10 %)	0.102	0.86 [0.71 to 1.03]	
	Smoker	2,239 (18.98 %)	2,184 (18.06 %)	0.069	1.06 [1.00 to 1.14]	
	~missing~	553 (4.48 %)	257 (2.08 %)			
Blood pressure (mmHg)	systolic	126 ± 19	125 ± 18	0.001		0.004
	diastolic	76.1 ± 10.0	76.0 ± 9.6	0.515		0.008
	~missing~	7 (0.057 %)	5 (0.040 %)			
Hypertension status	stage 1	2,419 (19.6 %)	2,402 (19.5 %)	0.785	1.01 [0.95 to 1.08]	
	stage 2	2,074 (16.8 %)	2,043 (16.5 %)	0.597	1.02 [0.95 to 1.09]	
Ethnic group	Arab	2,215 (17.9 %)	2,215 (17.9 %)	1.000	1.00 [0.94 to 1.07]	
	General	7,976 (64.6 %)	7,976 (64.6 %)	1.000	1.00 [0.95 to 1.05]	
	Jewish Ultra-orthodox	2,161 (17.5 %)	2,161 (17.5 %)	1.000	1.00 [0.94 to 1.07]	
Socio-economic status (1-20)		8.39 ± 3.68	8.57 ± 3.53	<0.001		-0.051
	~missing~	417 (3.38 %)	417 (3.38 %)			

This descriptive table summarizes baseline characteristics of the 1:1 matched LHS cohort comparing individuals with severe vitamin D deficiency (<10 ng/mL) and sufficiency (>30 ng/mL), with calendar adjustment applied to 25(OH)D (see Methods). Matching was performed on age category, sex, BMI category, smoking status, hypertension stage, socioeconomic status, and year of LHS enrollment; variables used for exact matching have similar counts across groups by design. The sufficiency group (>30 ng/mL) serves as the reference category for comparisons; "reference" denotes the a priori comparison category and does not imply majority prevalence.

Cohort characteristics are reported at the index date (the date of the first qualifying 25(OH)D measurement during the study period). Baseline covariates were taken as of the index date (using the closest pre-index measurement when available, and the first post-index measurement otherwise).

Continuous variables are presented as mean +/- SD; categorical variables as n (%). "missing" indicates no available baseline value for that variable. Percentages for categories are calculated out of the non-missing values.

P values are descriptive only and not used for inference or balance decisions in this matched design. For continuous variables, two-sample t-tests were used; for categorical variables, Fisher's exact test.

Odds ratios (ORs) are unadjusted and compare the odds of being in the Deficiency group vs the Sufficiency (reference) group for the listed level (95% CI in brackets). For multi-level variables, the OR shown is for each level vs all other levels of that variable.

SMD: standardized mean difference (|SMD| < 0.10 generally indicates negligible imbalance)

Table 2. Demographic and clinical characteristics of the US-TriNetX matched cohort at baseline (Analysis C)

		Severe Deficiency 25(OH)D < 10 ng/mL	Sufficiency 25(OH)D >30 ng/mL (reference)
N before matching		224,419	2,117,525
N after matching		223,175	223,175
Age	(years)	54.4 ± 14.8	54.5 ± 14.6
Sex	Female	65.2%	65.5%
	Male	34.8%	34.5%
Smoking status (nicotine dependence)		19.7%	19.8%
Black or African American		52.0%	53.9%
Essential hypertension		32.4%	32.6%
Diabetes Mellitus		28.2%	29.4%
Body Mass Index (BMI)	kg/m^2	32.1±9.1	31.9±8.5
	0-25	33.1%	31.7%
	25-30	42.7%	42.4%
	30-35	38.9%	39.9%
	35-40	27.8%	29.0%
	≥40	24.6%	25.8%
Blood pressure systolic	mmHg	127.5 ± 20.4	127.4 ± 18.3
	0-120	68.5%	69.4%
	120-140	79.4%	80.8%
	140-160	61.7%	63.1%
	≥160	37.4%	38.5%
Hemoglobin A1c	%	6.4±1.9	6.3±1.5
	0-5.7	30.1%	30.1%
	5.7-6.5	28.5%	29.8%
	6.5-7.5	15.2%	15.8%
	≥7.5	16.0%	16.5%
Fasting serum glucose	mg/dL	113.4 ± 53.4	109.5 ± 45.3
	≥100	72.0%	68.3%

This table summarizes baseline characteristics of the 1:1 propensity-score-matched US-TriNetX cohort, comparing individuals with severe vitamin D deficiency (< 10 ng/mL) and sufficiency (> 30 ng/mL) defined by their baseline serum 25(OH)D measurement, which served as the index date.

All included participants had at least one BMI measurement recorded within one year prior to the index date.

Propensity-score matching was performed on the covariates listed in the table, including age, sex, smoking status, Black or African-American ethnicity, essential hypertension, diabetes mellitus diagnosis, BMI, blood-pressure categories, and hemoglobin A1c categories.

The matched cohorts were well balanced across these covariates, demonstrating very similar distributions of age (mean ~ 54.4 years), sex (≈ 65 % female), cardiometabolic risk factors, and

laboratory measures at baseline. More than half of the cohort participants self-identified as Black or African American, reflecting the demographic distribution of severe vitamin D deficiency in the TriNetX network and its matched comparison group.

Table 3. Demographic and clinical characteristics of the Leumit Health Services (LHS) longitudinal cohort used for analysis of vitamin D supplementation (Analysis D)

N (individuals)		247,848
gender	**Female**	153,187 (61.8 %)
	Male	94,661 (38.2 %)
age (years)		51.8 ± 15.1
age category	**30-39**	63,929 (25.79 %)
	40-49	53,888 (21.74 %)
	50-59	55,087 (22.23 %)
	60-69	40,426 (16.31 %)
	70-79	22,183 (8.95 %)
	80-89	10,578 (4.27 %)
	90-	1,757 (0.71 %)
weight (kg)		76.8 ± 17.4
height (cm)		166 ± 10
BMI	**(kg/m^2)**	28.3 ± 5.8
	<18.5 Underweight	2,832 (1.60 %)
	18.5-24.9 Normal	49,649 (28.11 %)
	25-29.9 Overweight	63,692 (36.06 %)
	>=30 Obese	60,474 (34.23 %)
BP systolic (mmHg)		126 ± 18
BP diastolic (mmHg)		76.1 ± 10.2
BP category	**Hypertension 1**	53,456 (21.8 %)
	Hypertension 2	44,580 (18.2 %)
	Normal BP	146,660 (59.9 %)
Smoking status	**Non-smoker**	184,003 (78.46 %)
	Past smoker	5,680 (2.42 %)
	Smoker	44,822 (19.11 %)
	~missing~	13,343 (5.38 %)
Ethnic group	**Arab**	47,015 (19.0 %)
	General	164,408 (66.3 %)
	Jewish Ultra-orthodox	36,425 (14.7 %)

Characteristics of 247,848 LHS members aged ≥30 years included in the longitudinal supplementation analysis (Analysis D). This cohort includes all individuals with at least one serum 25(OH)D measurement during the study window and available baseline 25(OH)D levels after excluding those for whom no test could be found while not under supplementation (>0.2 ng/mL predicted contribution). Continuous variables are presented as mean ± SD, and categorical variables as counts (percentages).

Figure 1: Overview of the analyses performed, showing study populations, age thresholds, exposure definitions, matching, and statistical models used.

Figure 2: Seasonal variation and population distribution of serum 25(OH)D in LHS (Analysis A)

(A) Modeled seasonal fluctuation in serum 25(OH)D levels across the calendar year in the Leumit Health Services (LHS) population, showing a sinusoidal pattern with a nadir in mid-February and peak in late August. The 95% confidence interval is shown but appears nearly indistinguishable due to the large population size.
(B) Normogram translating observed 25(OH)D levels to their expected nadir values based on date of measurement, enabling standardization of vitamin D status across seasons.
(C) Sex-stratified distribution of mean nadir-adjusted vitamin D levels in the LHS population. Severe deficiency (<10 ng/mL) is substantially more common in females (20.4%) than in males (9.9%), whereas vitamin D sufficiency (>30 ng/mL) is uncommon in both sexes.

Figure 3: Cross-sectional baseline prevalence of chronic conditions by vitamin D status in LHS (Analysis B) and TriNetX (Analysis C)

A   Conditions present at index date in LHS

Condition before	Deficiency <10 ng/mL	Sufficiency >30 ng/mL (reference)		OR [95% CI]	P value
Foot/Toe Amputation	0.37%	0.09%		4.01 [2.04-8.62]	$p < 10^{-5}$
Diabetes Mellitus	20.31%	17.16%		1.23 [1.15-1.31]	$p < 10^{-9}$
Diabetic Retinopathy	3.65%	2.19%		1.69 [1.45-1.99]	$p < 10^{-10}$
Dementia	2.23%	1.20%		1.89 [1.53-2.33]	$p < 10^{-9}$
CVA	2.95%	1.67%		1.79 [1.50-2.14]	$p < 10^{-10}$
Myocardial Infarction	6.21%	4.52%		1.40 [1.25-1.57]	$p < 10^{-8}$
Dialysis	0.07%	0.10%		0.67 [0.24-1.77]	$p = 0.50$
Skin Malignancy	0.45%	1.02%		0.44 [0.31-0.61]	$p < 10^{-6}$

B   Conditions present at index date in TriNetX

Condition before	Deficiency <10 ng/mL	Sufficiency >30 ng/mL (reference)		OR [95% CI]	P value
Foot/Toe Amputation	0.36%	0.20%		1.81 [1.60 to 2.04]	$p < 10^{-21}$
Diabetes	28.00%	28.94%		0.95 [0.94 to 0.97]	$p < 10^{-10}$
Diabetic Retinopathy	2.99%	2.22%		1.36 [1.30 to 1.41]	$p < 10^{-53}$
Dementia	1.37%	1.07%		1.28 [1.21 to 1.35]	$p < 10^{-17}$
CVA	5.47%	3.93%		1.41 [1.37 to 1.46]	$p < 10^{-120}$
Myocardial Infarction	4.26%	2.97%		1.45 [1.40 to 1.50]	$p < 10^{-108}$
Hemodialysis	1.70%	1.04%		1.65 [1.56 to 1.74]	$p < 10^{-75}$
Skin Malignancy	1.62%	2.22%		0.72 [0.69 to 0.76]	$p < 10^{-45}$

(A) Odds ratios (OR) and 95% confidence intervals for preexisting conditions at cohort entry in the Leumit Health Services (LHS) matched cohort, comparing individuals with severe vitamin D deficiency (<10 ng/mL) to those with sufficient levels (>30 ng/mL).
(B) Corresponding analysis from the TriNetX propensity-matched cohort.

Conditions such as diabetes mellitus, diabetic retinopathy, dementia, myocardial infarction, and heart failure were consistently more prevalent in the vitamin D–deficient groups across both datasets. Foot/toe amputations showed the strongest association. In contrast, skin malignancy was significantly less common among individuals with low vitamin D, likely reflecting reduced cumulative UV exposure. These robust and replicated imbalances underscore the biological relevance of vitamin D status beyond demographic and behavioral confounding.

Figure 4: Longitudinal risk of mortality and incident disease by vitamin D status in LHS (left-panel) and TriNetX (right-panel)

A Mortality LHS

aHR = 2.57
CI [2.38 to 2.79]
$p < 10^{-308}$

mean Vitamin D < 10ng/mL
mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	11,659	11,386	10,904	10,384	9,854	8,970	7,902	7,000	6,255
VD>30	11,977	11,913	11,791	11,640	11,460	10,825	9,880	9,019	8,265

B Mortality TriNetX

HR = 1.59
CI [1.55 to 1.63]
$p < 1 \times 10^{-308}$

Vitamin D < 10 ng/mL
Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	199,788	150,397	132,019	117,699	104,702	92,800	82,358	71,282	59,889
VD>30	203,681	159,945	136,550	114,500	94,876	79,553	67,650	55,717	44,211

C Foot/Toe amputation LHS

aHR = 3.59
CI [2.15 to 5.98]
$p < 10^{-10}$

mean Vitamin D < 10ng/mL
mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	11,607	11,330	10,854	10,332	9,803	8,920	7,859	6,964	6,223
VD>30	11,966	11,902	11,781	11,628	11,447	10,811	9,871	9,007	8,255

D Foot/Toe amputation TriNetX

HR = 1.54
CI [1.38 to 1.72]
$p < 10^{-13}$

Vitamin D < 10 ng/mL
Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	204,663	172,515	151,434	135,008	120,100	106,447	94,469	81,765	68,697
VD>30	205,246	174,828	149,256	125,155	103,704	86,956	73,945	60,902	48,325

E Myocardial infarction LHS

aHR = 1.26
CI [1.10 to 1.46]
$p = 0.0009$

mean Vitamin D < 10ng/mL
mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	10,936	10,667	10,200	9,713	9,209	8,376	7,399	6,530	5,825
VD>30	11,424	11,339	11,187	10,998	10,808	10,180	9,290	8,461	7,759

F Myocardial infarction TriNetX

HR = 1.37
CI [1.33 to 1.42]
$p < 10^{-71}$

Vitamin D < 10 ng/mL
Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	195,351	162,862	142,961	127,454	113,380	100,491	89,184	77,190	64,853
VD>30	198,826	167,309	142,837	119,772	99,244	83,215	70,765	58,283	46,246

G Cerebrovascular accident LHS

aHR = 1.54
CI [1.32 to 1.78]
$p < 10^{-5}$

mean Vitamin D < 10ng/mL
mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	11,290	11,014	10,513	10,010	9,482	8,629	7,600	6,715	6,004
VD>30	11,773	11,703	11,559	11,377	11,191	10,568	9,625	8,777	8,029

H Cerebrovascular accident TriNetX

HR = 1.36
CI [1.31 to 1.40]
$p < 10^{-69}$

Vitamin D < 10 ng/mL
Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	192,740	162,257	142,430	126,981	112,959	100,118	88,852	76,903	64,612
VD>30	196,767	166,795	142,398	119,404	98,939	82,960	70,548	58,104	46,104

I Dementia LHS

aHR = 1.35
CI [1.20 to 1.52]
$p = 0.02$

LHS Numbers at risk

VD<10	11,370	11,088	10,577	10,050	9,531	8,675	7,631	6,762	6,052
VD>30	11,815	11,732	11,585	11,395	11,195	10,533	9,586	8,727	7,978

J Dementia TriNetX

HR = 1.18
CI [1.13 to 1.24]
$p < 10^{-11}$

TriNetX Numbers at risk

VD<10	202,899	169,258	148,632	132,541	117,944	104,589	92,873	80,431	67,660
VD>30	203,919	171,743	146,438	122,983	102,053	85,596	72,878	60,099	47,703

K Diabetic retinopathy LHS

aHR = 1.73
CI [1.42 to 2.10]
$p < 10^{-8}$

LHS Numbers at risk

VD<10	11,201	10,924	10,456	9,945	9,421	8,563	7,535	6,661	5,945
VD>30	11,703	11,635	11,505	11,343	11,163	10,517	9,591	8,744	8,010

L Diabetic retinopathy TriNetX

HR = 1.34
CI [1.27 to 1.42]
$p < 10^{-24}$

TriNetX Numbers at risk

VD<10	198,598	169,589	148,867	132,719	118,063	104,642	92,868	80,378	67,532
VD>30	200,676	172,412	147,194	123,426	102,271	85,754	72,923	60,061	47,657

M Hemodialysis LHS

aHR = 1.84
CI [1.13 to 2.99]
$p = 0.0005$

LHS Numbers at risk

VD<10	11,649	11,375	10,891	10,365	9,834	8,950	7,885	6,984	6,238
VD>30	11,965	11,901	11,779	11,623	11,441	10,807	9,866	9,008	8,255

N Hemodialysis TriNetX

HR = 2.07
CI [1.96 to 2.19]
$p < 10^{-151}$

TriNetX Numbers at risk

VD<10	200,008	168,430	147,849	131,812	117,256	103,927	92,233	79,829	67,070
VD>30	203,259	172,845	147,563	123,736	102,528	85,969	73,107	60,211	47,777

O Skin Malignancy LHS

aHR = 0.57
CI [0.47 to 0.70]
$p < 10^{-13}$

LHS Numbers at risk

VD<10	11,595	11,323	10,838	10,303	9,765	8,878	7,813	6,930	6,183
VD>30	11,843	11,764	11,621	11,435	11,229	10,581	9,635	8,784	8,028

P Skin Malignancy TriNetX

HR = 0.66
CI [0.63 to 0.69]
$p < 10^{-65}$

TriNetX Numbers at risk

VD<10	201,873	169,588	148,866	132,718	118,063	104,642	92,867	80,378	67,531
VD>30	200,677	169,349	144,579	121,233	100,454	84,230	71,628	58,993	46,811

Kaplan-Meier survival and cumulative incidence curves for matched cohorts of adults ≥30 years, comparing individuals with baseline serum 25(OH)D <10 ng/mL vs >30 ng/mL across two independent cohorts: Leumit Health Services (LHS, left panels) and TriNetX (right panels). Time is years since the index (first qualifying 25(OH)D test). Numbers at risk are shown below each plot. Only incident events occurring ≥6 months after the index date were included; individuals with events in the first year after index were excluded prior to analysis.

Panels: (A–B) All-cause mortality; (C–D) Foot/toe amputation; (E–F) Myocardial infarction; (G–H) Cerebrovascular accident; (I–J) Dementia; (K–L) Diabetic Retinopathy; (M–N) Hemodialysis initiation; (O–P) Skin malignancy.

LHS (left): Adjusted hazard ratios (aHRs), 95% CI, and P values are from Cox models fit in the 1:1 exact-matched cohort (Table 1) and further adjusted for age (continuous), sex, socioeconomic status (fine categories), baseline diabetes (ICD-9 diagnosis or HbA1c >6.5), smoking status (never, past, current, or missing), BMI (fine categories plus an offset from the category lower boundary), kidney function (GFR categories), and albuminuria (urinary albumin/creatinine categories). The reference category is vitamin D sufficiency (>30 ng/mL).

TriNetX (right): Hazard Ratios (HRs), 95% CIs, and P values are from Cox models in 1:1 propensity score matched cohorts (Table 2), balanced on age at index, current age, sex, ethnicity, race, diabetes diagnosis, BMI, GFR, glucose, hemoglobin, AST, ALT, HDL, LDL, and HbA1c. A 6-month lag was applied as above. The reference category is vitamin D sufficiency (>30 ng/mL).

.

Figure 5: Longitudinal joint effects of baseline vitamin D status and supplementation on health outcomes in LHS (Analysis D) in LHS

A Mortality

B Diabetes Mellitus

C Diabetic Retinopathy

D Myocardial Infarction

E Foot/Toe Amputation

F Skin Malignancy

Adjusted hazard ratios (HRs) with 95 % confidence intervals (log scale) are shown for mortality and five clinical outcomes among all Leumit Health Services (LHS) members aged ≥30 years who had at least one serum

25(OH)D measurement since 2009. The index date was defined as the first available measurement within the study window.

Cox proportional-hazards models jointly included baseline serum 25(OH)D categories (0–5, 5–10, 10–15, 15–20 ng/mL; reference 20–30 ng/mL) and vitamin D supplementation categories modeled time-dependently from pharmacy dispensing records (0.2–5, 5–10, >10 ng/mL serum-equivalent; reference <0.2 ng/mL). Models were adjusted for age, sex, smoking status, socioeconomic status, BMI (fine categories plus offset), estimated GFR category, albuminuria category, and baseline diabetes, and applied a 6-month lag to minimize reverse causation from early events.

An HR < 1 indicates lower risk; HR > 1 indicates higher risk. The vertical dashed line marks HR = 1.
Panels: (A) Mortality, (B) Diabetes mellitus, (C) Diabetic retinopathy, (D) Myocardial infarction, (E) Foot/Toe amputation, (F) Skin malignancy.

Higher baseline 25(OH)D and increasing supplementation dose were consistently associated with lower risks of outcomes in panels A–D. Panel F served as a negative-control outcome: it showed an inverse association with baseline vitamin D (likely reflecting higher sun exposure in individuals with higher baseline 25(OH)D) but no association with supplementation calculated from pharmacy supply.

Figure 6: Estimated 10-year number needed to treat (NNT) for prevention of all-cause mortality by age, baseline vitamin D status, and supplementation level in LHS (Analysis D).

Panels A–C show the estimated 10-year number needed to treat (NNT) to prevent one death for each vitamin D supplementation category (color-coded bars), stratified by baseline serum 25(OH)D concentration (groups of

columns) and by age threshold (rows: $\geq$30, $\geq$50, $\geq$70 years). Supplementation categories are defined by the modeled increase in serum 25(OH)D (ng/mL). Error bars represent 95 % confidence intervals.
NNT values were derived from absolute risk reductions estimated from the joint time-dependent Cox proportional-hazards models (see Methods).
NNT declined markedly with older age and with lower baseline 25(OH)D ($<$10 ng/mL), reaching approximately 10–15 in older adults with very low baseline levels—indicating a substantial preventive benefit of vitamin D supplementation in these high-risk groups.